Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.63 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17283465 | 1.00 | PTGS2 (0.63) | PTGS2ALDH1A3ALDH1A1MEN1KMT2A | |
| Hydrogen Sulfide SCHEMBL19086306 | 0.97 | PTGS2 (0.61) | PTGS2ALDH1A3ALDH1A1MEN1KMT2A | |
| Bicarbonate SCHEMBL29125500 | 0.91 | PTGS2 (0.60) | PTGS2ALDH1A3MEN1KMT2AHAO1 | |
| SCHEMBL27299439 | 0.91 | PTGS2 (0.55) | PTGS2ALDH1A3ALDH1A1MEN1KMT2A | |
| Bicarbonate SCHEMBL28112658 | 0.91 | PTGS2 (0.60) | PTGS2ALDH1A3MEN1KMT2AHAO1 | |
| Biphenyl SCHEMBL27610807 | 0.91 | PTGS2 (0.55) | PTGS2ALDH1A3ALDH1A1MEN1KMT2A | |
| SCHEMBL10528160 | 0.88 | ALDH1A1 (0.50) | PTGS2ALDH1A1PTGS1HAO1 | |
| SCHEMBL10300271 | 0.88 | ALDH1A1 (0.50) | PTGS2ALDH1A1PTGS1HAO1 | |
| SCHEMBL6247727 | 0.87 | PTGS2 (0.57) | PTGS2ALDH1A3ALDH1A1MEN1KMT2A | |
| SCHEMBL19114473 | 0.87 | PTGS2 (0.52) | PTGS2ALDH1A3ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114031565-A | N, N' -disubstituted dihydrophenazine-based compound and preparation method and application thereof | 华东理工大学 | 2022-02-11 | — | — | CN | claimed |
| CN-111875525-A | Cationic sulfoxide intermediate, polyarylene sulfide monomer and preparation method of polyarylene sulfide | 财团法人工业技术研究院 | 2020-11-03 | — | — | CN | claimed |
| CN-106986803-A | Cationic sulfoxide intermediate, polyarylene sulfide monomer and preparation method of polyarylene sulfide | 财团法人工业技术研究院 | 2017-07-28 | — | — | CN | claimed |
| EP-4570317-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2025-06-18 | — | — | EP | disclosed |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | INTERVET INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | INTERVET INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | INTERVET INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-4212519-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LT Materials Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023115327-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | 中国药科大学 | 2023-06-29 | — | — | WO | disclosed |
| US-20230200227-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-110072844-B | Compounds for the treatment of infection by Mannheimia haemolytica or histophilus somni | 英特维特国际股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-1294657-A2 | CATALYSIS USING PHOSPHINE OXIDE AND SULFOXIDE COMPOUNDS | E. I. du Pont de Nemours and Company (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020137974-A1 | Catalysis using phosphine oxide and sulfoxide compounds | DUPONT POLYMERS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-6410594-B1 | VIRICIDES | BIOCRYST PHARMACEUTICALS, INC. | 2002-06-25 | — | — | US | disclosed |
| WO-2002000574-A2 | CATALYSIS USING PHOSPHINE OXIDE AND SULFOXIDE COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| CN-1227466-A | Substituted cyclopentane compounds useful as neuraminidase inhibitors | BIOCRYST PHARM INC (US) | 1999-09-01 | — | — | CN | disclosed |
| EP-0933993-A1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS INC. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997047194-A1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| EP-0794942-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016934-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | SORD, HEXD, SNRPD1 | PTGS2 772/4885ALDH1A3 712/4885ALDH1A1 1559/4885 |
| US-20020137974-A1 | Catalysis using phosphine oxide and sulfoxide compounds | TST, GSS, ARSA | PTGS2 1085/4885ALDH1A3 2317/4885ALDH1A1 2774/4885 |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | SORD, HEXD, SNRPD1 | PTGS2 1037/4885ALDH1A3 1119/4885ALDH1A1 2263/4885 |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | PIGS, BTD, PPARD | PTGS2 927/4885ALDH1A3 784/4885ALDH1A1 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.